These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36738637)

  • 1. Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges.
    Yu Y; Yang Y; Li H; Fan Y
    Cancer Treat Rev; 2023 Mar; 114():102520. PubMed ID: 36738637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
    Riudavets M; Sullivan I; Abdayem P; Planchard D
    ESMO Open; 2021 Oct; 6(5):100260. PubMed ID: 34479034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
    von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
    Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab Deruxtecan in
    Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
    N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis.
    Wu HX; Zhuo KQ; Wang K
    Br J Clin Pharmacol; 2022 May; 88(5):2019-2034. PubMed ID: 34820879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC.
    Cancer Discov; 2021 Dec; 11(12):OF3. PubMed ID: 34675060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of Non-Small Cell Lung Cancer with HER2 Alterations].
    Takakura T; Yamamoto N
    Gan To Kagaku Ryoho; 2023 Jul; 50(7):768-772. PubMed ID: 37496218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.
    Shiraishi A; Oh-Hara T; Takahashi Y; Uchibori K; Nishio M; Katayama R
    Biochem Biophys Res Commun; 2024 Sep; 725():150255. PubMed ID: 38897043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.
    Cancer Discov; 2022 Oct; 12(10):2224. PubMed ID: 35984233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
    Indini A; Rijavec E; Grossi F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic
    Yun KM; Bazhenova L
    BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy.
    Falk M; Willing E; Schmidt S; Schatz S; Galster M; Tiemann M; Ficker JH; Brueckl WM
    Curr Oncol; 2023 Jan; 30(2):1692-1698. PubMed ID: 36826091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus for HER2 alterations testing in non-small-cell lung cancer.
    Ren S; Wang J; Ying J; Mitsudomi T; Lee DH; Wang Z; Chu Q; Mack PC; Cheng Y; Duan J; Fan Y; Han B; Hui Z; Liu A; Liu J; Lu Y; Ma Z; Shi M; Shu Y; Song Q; Song X; Song Y; Wang C; Wang X; Wang Z; Xu Y; Yao Y; Zhang L; Zhao M; Zhu B; Zhang J; Zhou C; Hirsch FR
    ESMO Open; 2022 Feb; 7(1):100395. PubMed ID: 35149428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
    Nakano K
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer).
    Gaye E; Penel N; Lebellec L
    Curr Opin Oncol; 2022 Sep; 34(5):570-574. PubMed ID: 35943440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
    Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT
    Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies.
    Uy NF; Merkhofer CM; Baik CS
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer.
    Liu J; Zhu T; Zhao R; Ren W; Zhao F; Liu J
    Gastric Cancer; 2024 May; 27(3):495-505. PubMed ID: 38386239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.